首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備 DDS

市場調查報告書

商品編碼

1532613

藥物器材組合產品市場規模 - 按產品、應用、最終用途和全球預測，2024 年 - 2032 年

Drug Device Combination Products Market Size - By Product, Application, End-use & Global Forecast, 2024 - 2032

出版日期: 2024年05月28日 | 出版商:

Global Market Insights Inc. | 英文 230 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在技術進步和研發力度加大的推動下，藥物器材組合產品市場規模預計從 2024 年到 2032 年複合年成長率將達到 7.8%。最近，製造商正在將尖端技術整合到藥物器械組合產品中，以提高其有效性和用戶便利性。正在進行的研究正在幫助開發更精確、更可靠的設備，以改善藥物傳輸和患者治療結果。

因此，對技術和創新的投資正在推動發展，以確保這些產品在治療一系列疾病方面變得更加複雜和有效。例如，2022年12月，Terumo公司與Kyowa Kirin合作推出了藥物設備組合「G-Lasta皮下注射3.6毫克BodyPod」。本產品將自動注射器與聚乙二醇非格司亭結合起來，以減少化療患者的發燒性嗜中性白血球減少症。

藥物器材組合產品市場分為產品、應用、最終用途和區域。

在產品方面，由於先進技術與藥物輸送系統的高度整合以改善治療效果，因此吸入器領域預計從 2024 年到 2032 年將錄得顯著的複合年成長率。製造商正在開發新型吸入器，將精密設備與藥物結合，以更有效地管理呼吸系統疾病。此外，整合智慧技術等功能來追蹤使用情況並確保正確用藥依從性的不斷進步將推動該細分市場的成長。

從應用來看，在改善患者治療效果的需求不斷成長的推動下，心血管疾病領域的藥物器械組合產品產業預計到 2032 年將會成長。這些產品透過結合藥物和設備來提供創新的解決方案，以解決各種心血管疾病。此外，醫療專業人員正在利用這些先進的組合來提高治療效果和患者的依從性。正在進行的研究也正在塑造心血管疾病的治療方式，以期為個人提供更量身定做和更有效的治療方法。

從地區來看，在人口老化加劇和慢性病盛行率激增的推動下，亞太地區藥物器械組合產品市場規模預計將在 2024 年至 2032 年間呈現強勁成長。亞太地區的研究人員正在開發先進的組合產品，以滿足老年人和慢性病患者日益成長的醫療保健需求。的發展。

產業生態系統分析
產業影響力
- 成長動力
  - 對微創給藥裝置的需求不斷增加
  - 技術進步
  - 慢性病盛行率增加
- 產業陷阱與挑戰
  - 與藥物器械組合產品相關的高成本
  - 藥物傳遞的技術挑戰
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
藥物洗脫支架
- 冠狀動脈藥物支架
- 周邊藥物洗脫支架
點滴幫浦
- 植入式輸液泵
- 胰島素輸注泵
- 病人自控鎮痛泵
- 流動輸液幫浦
- 容量輸液泵
- 一次性使用輸液泵
光動力療法
傷口護理組合產品
預充式注射器
- 單室預灌封注射器
- 雙室預灌封注射器
- 客製化預灌封注射器
藥物洗脫球囊
- 冠狀動脈藥物洗脫球囊
- 周邊藥物洗脫球囊
霧化器
吸入器
- 藥物粉末吸入器 (DPI)
- 定量吸入器 (MDI)
- 軟霧吸入器 (SMI)
經皮給藥系統
- 主動經皮系統
- 被動經皮系統
骨科組合產品
- 骨移植植入物
- 抗生素骨水泥
抗菌導管
- 泌尿導管
- 心血管導管
- 其他導管
其他產品

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
心血管疾病
糖尿病
呼吸系統問題
癌症治療
抗菌應用
其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院和診所
門診手術中心
家庭護理設置
其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abbott Laboratories
AbbVie, Inc.
Alcon, Inc.
Bausch Health Companies Inc
Baxter International Inc.
Bayer AG
Becton, Dickinson and Company
Boston Scientific Corporation
GlaxoSmithKline plc
Johnson & Johnson
Kaleo, Inc.
Medtronic plc
Novartis AG
SINOMED
Smith & Nephew plc
Teleflex Incorporated
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 9674

Drug Device Combination Products Market size is projected to record 7.8% CAGR from 2024 to 2032, driven by technological advancements and increasing R&D efforts. Of late, manufacturers are integrating cutting-edge technologies into drug device combination products to enhance their effectiveness and user convenience. Ongoing research is helping in developing more precise and reliable devices to improve drug delivery and patient outcomes.

Consequently, investments in technology and innovation are driving developments for ensuring that these products become more sophisticated and effective in treating a range of conditions. For instance, in December 2022, Terumo Corporation in collaboration with Kyowa Kirin introduced a drug-device combination "G-Lasta Subcutaneous Injection 3.6 mg BodyPod". This product combines an automated injector with pegfilgrastim to reduce febrile neutropenia in chemotherapy patients.

The drug device combination products market is segregated into product, application, end-use, and region.

In terms of product, the inhalers segment is expected to record significant CAGR from 2024 to 2032 due to the high integration of advanced technologies with medication delivery systems to improve treatment outcomes. Manufacturers are developing new inhalers that combine precision devices with medications to manage respiratory conditions more effectively. Moreover, the increasing advancements for incorporating features like smart technology to track usage and ensure proper medication adherence will drive the segment growth.

By application, the drug device combination products industry from the cardiovascular disorders segment is projected to rise through 2032, driven by increasing demand to improve patient outcomes. These products are providing innovative solutions by combining drugs and devices to address various cardiovascular conditions. Additionally, medical professionals are utilizing these advanced combinations to enhance treatment efficacy and patient compliance. Ongoing research is also shaping the way cardiovascular disorders are treated for promising more tailored and effective therapies for individuals.

Regionally, the Asia Pacific drug device combination products market size is projected to exhibit robust growth between 2024 and 2032, fueled by the increasing aging population and surging prevalence of chronic diseases. Researchers in APAC are developing advanced combination products to address the growing healthcare needs of older adults and those with chronic conditions The continuous advancements for enhancing combination products with improvements in drug delivery systems and integration with digital health technologies will boost the regional industry development.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for minimally invasive drug delivery devices
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Increasing prevalence of chronic diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with drug device combination products
  - 3.2.2.2 Technical challenges in drug delivery
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Drug-eluting stents
- 5.2.1 Coronary drug-elating stents
- 5.2.2 Peripheral drug-eluting stents
5.3 Infusion pumps
- 5.3.1 Implantable infusion pumps
- 5.3.2 Insulin infusion pumps
- 5.3.3 Patient-controlled analgesia pumps
- 5.3.4 Ambulatory infusion pumps
- 5.3.5 Volumetric infusion pumps
- 5.3.6 Disposable infusion pumps
5.4 Photodynamic therapy
5.5 Wound care combination product
5.6 Prefilled syringes
- 5.6.1 Single-chamber prefilled syringes
- 5.6.2 Dual-chamber prefilled syringes
- 5.6.3 Customized prefilled syringes
5.7 Drug-eluting balloons
- 5.7.1 Coronary drug-eluting balloons
- 5.7.2 Peripheral drug-eluting balloons
5.8 Nebulizers
5.9 Inhalers
- 5.9.1 Drug powdered inhalers (DPIs)
- 5.9.2 Metered dose inhalers (MDIs)
- 5.9.3 Soft mist inhalers (SMIs)
5.10 Transdermal delivery systems
- 5.10.1 Active transdermal systems
- 5.10.2 Passive transdermal systems
5.11 Orthopedic combination products
- 5.11.1 Bone graft implants
- 5.11.2 Antibiotic loaded bone cement
5.12 Antimicrobial catheters
- 5.12.1 Urological catheters
- 5.12.2 Cardiovascular catheters
- 5.12.3 Other catheters
5.13 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Cardiovascular disorders
6.3 Diabetes
6.4 Respiratory problems
6.5 Cancer treatment
6.6 Antimicrobial application
6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals and clinics
7.3 Ambulatory surgical centers
7.4 Home care settings
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa